DC
CYCN icon

Diametric Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Diametric Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,186
Closed -$210K – 318
2022
Q3 		$210K Buy
12,186
+9
+0.1% +$155 0.11% 216
2022
Q2 		$134K Buy
12,177
+3,030
+33% +$43.4K 0.1% 219
2022
Q1 		$203K Buy
9,147
+4,123
+82% +$99.3K 0.11% 186
2021
Q4 		$173K Buy
5,024
+1,533
+44% +$72.4K 0.13% 139
2021
Q3 		$214K Sell
3,491
-526
-13% -$34.4K 0.17% 112
2021
Q2 		$313K Buy
+4,017
New +$252K 0.23% 97

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Diametric Capital's CYCN Position: Q4 2022 in Review

Diametric Capital sold out of Cyclerion Therapeutics (CYCN) in Q4 2022, closing a stake of 12,186 shares — an estimated $210K sold.

Diametric Capital first reported a position in CYCN in Q2 2021 and held it in 6 quarters. The position peaked at $313K in Q2 2021. 40 funds tracked by Wall St. Rank hold CYCN as of Q4 2022.

  • Diametric Capital reported no remaining Cyclerion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Diametric Capital sold 12,186 Cyclerion Therapeutics shares in Q4 2022, an estimated $210K.
  • Diametric Capital first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 6 quarters.
  • Diametric Capital's Cyclerion Therapeutics position peaked at $313K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2022.

Based on Diametric Capital's 13F filing for Q4 2022, filed 29 Mar 2023.